Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions
Abstract Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads, leading to improved tumor delivery of the latter. After improving outcomes for patients with metastatic disease, ADC testing moved to the curative setting, where already one agen...
Saved in:
| Main Authors: | Pooja Patel, Antonio Giordano, Sara Giordano, Ilana Schlam, Sara M. Tolaney, Paolo Tarantino |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00800-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current status and future perspectives of antibody-drug conjugates in breast cancer therapy
by: LIN Jialin, WANG Wenna, XU Binghe
Published: (2025-02-01) -
Current issues with antibody-conjugated lipid nanoparticles
by: Aayush
Published: (2025-02-01) -
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
by: Ruili Wang, et al.
Published: (2025-04-01) -
Antibody-drug conjugates in breast cancer: advances and prospects
by: Zhiqiang Shi, et al.
Published: (2025-02-01) -
Dynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients
by: Xiaopeng Sun, et al.
Published: (2025-07-01)